Why the study?
Pediatric hypertension management remains challenging due to limited safety and efficacy trials, pharmacokinetics, and unknown risks of prolonged exposure, prompting a review of safety and efficacy literature for commonly prescribed antihypertensive agents.
Design
Literature review
Authors
Loading...
Supports ACE-I/ARB/CCB selection in pediatric hypertension per current data; leaves open trials on beta-blockers, vasodilators, and long-term safety.
While ACE-I, ARBs, and CCBs have the most data supporting their use in pediatric hypertension, significant gaps remain regarding long-term safety and the use of other antihypertensive classes.
Siddiqi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: